(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Theravance Biopharma's revenue in 2024 is $57,424,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2024 to be $3,234,067,483, with the lowest TBPH revenue forecast at $3,077,724,841, and the highest TBPH revenue forecast at $3,448,111,446. On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $4,325,479,767, with the lowest TBPH revenue forecast at $4,123,380,652, and the highest TBPH revenue forecast at $4,647,894,322.
In 2026, TBPH is forecast to generate $6,724,419,378 in revenue, with the lowest revenue forecast at $5,876,094,376 and the highest revenue forecast at $8,026,166,941.